SPEVIGO
Total Payments
$14.8M
Transactions
19,616
Doctors
8,237
Companies
5
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $12.5M | 9,334 | 5,186 |
| 2023 | $1.1M | 7,540 | 4,605 |
| 2022 | $1.3M | 2,742 | 2,312 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $12.3M | 175 | 83.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.0M | 590 | 6.9% |
| Consulting Fee | $794,451 | 286 | 5.4% |
| Food and Beverage | $525,387 | 18,176 | 3.6% |
| Travel and Lodging | $114,609 | 364 | 0.8% |
| Education | $250.98 | 25 | 0.0% |
Payments by Type
Research
$12.3M
175 transactions
General
$2.5M
19,441 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Charact. PG Lesion Regression+Remission by IL-36 with Speso | Boehringer Ingelheim Pharmaceuticals, Inc. | $9.2M | 0 |
| Speso moderate to severe HS Phase IIb/III | Boehringer Ingelheim Pharmaceuticals, Inc. | $1.2M | 0 |
| Safety & Efficacy of Speso in Pts with Netherton Syndrome | Boehringer Ingelheim Pharmaceuticals, Inc. | $311,331 | 0 |
| Open Label Extension | Boehringer Ingelheim Pharmaceuticals, Inc. | $310,473 | 0 |
| 5 Years OLE Phase II Trial in PPP | Boehringer Ingelheim Pharmaceuticals, Inc. | $279,711 | 0 |
| Phase II Anti IL36R treatment of fibrostenotic CD | Boehringer Ingelheim Pharmaceuticals, Inc. | $273,158 | 0 |
| PoCC Dose ranging in HS | Boehringer Ingelheim Pharmaceuticals, Inc. | $144,113 | 0 |
| Postmarked Study for Flare Retreatment | Boehringer Ingelheim Pharmaceuticals, Inc. | $100,926 | 0 |
| Defining IL-36 as a crit. amplification circuit in skin infl | Boehringer Ingelheim Pharmaceuticals, Inc. | $99,806 | 0 |
| Long term open label treatm. with BI655130 in pat. | Boehringer Ingelheim Pharmaceuticals, Inc. | $77,030 | 0 |
| Long term extension | Boehringer Ingelheim Pharmaceuticals, Inc. | $61,701 | 0 |
| Dose finding Trial in PPP Phase II | Boehringer Ingelheim Pharmaceuticals, Inc. | $56,991 | 0 |
| 5 Years OLE Phase III Trial in GPP | Boehringer Ingelheim Pharmaceuticals, Inc. | $53,043 | 0 |
| Speso moderate to severe HS Phase IIb/III | Boehringer Ingelheim International GmbH | $42,232 | 0 |
| Phase 2 longterm Open Label Extension Study in UC | Boehringer Ingelheim Pharmaceuticals, Inc. | $26,706 | 0 |
| Postmarked Study for Flare Retreatment | Boehringer Ingelheim International GmbH | $17,338 | 0 |
| Long term extension | Boehringer Ingelheim International GmbH | $16,382 | 0 |
| Flare Prevention Phase IIb Trial in GPP | Boehringer Ingelheim Pharmaceuticals, Inc. | $15,928 | 0 |
| Phase II III in UC patients | Boehringer Ingelheim Pharmaceuticals, Inc. | $15,750 | 0 |
| Flare Prevention Phase III Trial in GPP | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,917 | 0 |
Top Doctors Receiving Payments for SPEVIGO
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Emma Larson | — | Cleveland, OH | $12.3M | 298 |
| , P.A | Anesthesiologist Assistant | Atlanta, GA | $101,622 | 49 |
| , M.D | Dermatology | Lancaster, TX | $100,604 | 53 |
| , M.D | MOHS-Micrographic Surgery | Forney, TX | $89,962 | 39 |
| , M.D | Clinical & Laboratory Dermatological Immunology | Waterford, MI | $73,790 | 67 |
| , MD, MS | Dermatology | Salt Lake City, UT | $69,489 | 38 |
| , MD | Dermatology | Wellington, FL | $65,990 | 35 |
| , MD | Dermatology | Los Angeles, CA | $63,166 | 38 |
| , MD | Student in an Organized Health Care Education/Training Program | New York, NY | $57,234 | 40 |
| , M.D | Internal Medicine | Washington, DC | $56,790 | 44 |
| , DO | Dermatology | Upper Sandusky, OH | $55,116 | 55 |
| , M.D | Dermatology | Cromwell, CT | $51,018 | 76 |
| , MD | Dermatology | Bellevue, WA | $50,844 | 28 |
| , M.D | Dermatology | Lewisville, TX | $49,422 | 28 |
| , M.D., PH.D | Dermatology | Wausau, WI | $48,799 | 41 |
| , MD | Dermatology | San Diego, CA | $43,192 | 31 |
| Laura Ferris | Specialist | Pittsburgh, PA | $42,947 | 29 |
| , MD, MPA, MPH | Internal Medicine | Boston, MA | $39,644 | 28 |
| Theodore Daly | — | Garden City, NY | $39,307 | 25 |
| , MD, PHD | Dermatology | Las Vegas, NV | $36,915 | 31 |
| Mark Lebwohl | Dermatology | New York, NY | $33,141 | 77 |
| , M.D., PH.D | Dermatology | Chicago, IL | $27,316 | 17 |
| , M.D | Dermatology | New York, NY | $27,237 | 39 |
| , PAC | Physician Assistant | Rome, GA | $25,295 | 21 |
| , M.D | Dermatology | Los Angeles, CA | $21,967 | 11 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $14.8M
- Total Doctors 8,237
- Transactions 19,616
About SPEVIGO
SPEVIGO is a drug associated with $14.8M in payments to 8,237 healthcare providers, recorded across 19,616 transactions in the CMS Open Payments database. The primary manufacturer is Boehringer Ingelheim Pharmaceuticals, Inc..
Payment data is available from 2022 to 2024. In 2024, $12.5M was paid across 9,334 transactions to 5,186 doctors.
The most common payment nature for SPEVIGO is "Unspecified" ($12.3M, 83.4% of total).
SPEVIGO is associated with 20 research studies, including "Charact. PG Lesion Regression+Remission by IL-36 with Speso" ($9.2M).